We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+13.66%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$14.8B
AUM Growth
+$2.81B
(+24%)
Cap. Flow
+$1.65B
Cap. Flow
% of AUM
11.18%
Top 10 Holdings %
Top 10 Hldgs %
32.19%
Holding
1,185
New
65
Increased
729
Reduced
346
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$323M |
| 2 |
iShares China Large-Cap ETF
FXI
|
+$107M |
| 3 |
Texas Instruments
TXN
|
+$85.9M |
| 4 |
Tesla
TSLA
|
+$67.3M |
| 5 |
Intel
INTC
|
+$65.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$45M |
| 2 |
NVIDIA
NVDA
|
+$36.4M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$26.7M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$21.1M |
| 5 |
JPMorgan Chase
JPM
|
+$19.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 42.08% |
| 2 | Financials | 11.46% |
| 3 | Healthcare | 8.37% |
| 4 | Energy | 5.47% |
| 5 | Consumer Discretionary | 4.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
301
Madrigal Pharmaceuticals
MDGL
$11.1B
| $6.82M | 0.05% |
28,135
-77,255
| -73% | -$21.1M |
|
302
GE Aerospace
GE
$383B
| $6.8M | 0.05% |
89,120
-18,728
| -17% | -$1.25M |
|
|
HZNP
303
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.75M | 0.05% |
61,866
-21,019
| -25% | -$2.32M |
|
304
Vaxcyte
PCVX
$7.73B
| $6.74M | 0.05% |
179,881
-10,421
| -5% | -$442K |
|
305
Cytokinetics
CYTK
$10.4B
| $6.73M | 0.05% |
191,154
-34,223
| -15% | -$1.4M |
|
306
Sarepta Therapeutics
SRPT
$1.68B
| $6.7M | 0.05% |
48,646
-21,988
| -31% | -$2.85M |
|
307
Magnolia Oil & Gas
MGY
$5.96B
| $6.7M | 0.05% |
306,336
-30,711
| -9% | -$682K |
|
308
Iovance Biotherapeutics
IOVA
$1.93B
| $6.69M | 0.05% |
1,095,439
-70,259
| -6% | -$485K |
|
309
United Therapeutics
UTHR
$25.7B
| $6.67M | 0.05% |
29,791
+1,019
| +4% | +$251K |
|
310
Arrowhead Research
ARWR
$12.1B
| $6.67M | 0.05% |
262,431
-9,917
| -4% | -$312K |
|
311
Zscaler
ZS
$25B
| $6.6M | 0.04% |
56,511
+7,046
| +14% | +$845K |
|
|
FOLD
312
DELISTED
Amicus Therapeutics
FOLD
| $6.6M | 0.04% |
594,701
-95,068
| -14% | -$1.17M |
|
313
Ironwood Pharmaceuticals
IRWD
$728M
| $6.55M | 0.04% |
622,175
-58,837
| -9% | -$659K |
|
314
CrowdStrike
CRWD
$206B
| $6.53M | 0.04% |
190,388
-10,952
| -5% | -$317K |
|
315
Twist Bioscience
TWST
$6.29B
| $6.5M | 0.04% |
431,068
+100,718
| +30% | +$2.22M |
|
316
Veracyte
VCYT
$3.58B
| $6.48M | 0.04% |
290,746
+9,018
| +3% | +$218K |
|
317
Beam Therapeutics
BEAM
$2.67B
| $6.48M | 0.04% |
211,668
+16,943
| +9% | +$669K |
|
318
TJX Companies
TJX
$174B
| $6.46M | 0.04% |
82,440
+6,841
| +9% | +$538K |
|
|
MRTX
319
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.45M | 0.04% |
173,516
-19,557
| -10% | -$880K |
|
320
Insmed
INSM
$21.3B
| $6.45M | 0.04% |
378,248
-58,554
| -13% | -$1.14M |
|
321
lululemon athletica
LULU
$14B
| $6.44M | 0.04% |
17,677
+3,828
| +28% | +$1.2M |
|
322
Palo Alto Networks
PANW
$283B
| $6.43M | 0.04% |
64,404
-5,940
| -8% | -$503K |
|
323
East-West Bancorp
EWBC
$18.1B
| $6.42M | 0.04% |
115,721
+84,157
| +267% | +$5.81M |
|
324
Boston Scientific
BSX
$72B
| $6.41M | 0.04% |
128,166
+4,932
| +4% | +$232K |
|
|
RXDX
325
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $6.38M | 0.04% |
59,464
-13,725
| -19% | -$1.58M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, Rafferty Asset Management held 1,185 positions worth $14.8B, up 24% from $11.9B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Rafferty Asset Management deployed $1.65B of net new capital in Q1 2023, opening 65 new positions and adding to 729 existing holdings. Its largest new stake was Flagstar Bank National Association: 362,459 shares worth $9.83M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 35% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was iShares Core S&P 500 ETF, an estimated $45M trimmed.
- Rafferty Asset Management's largest Q1 2023 buy was Flagstar Bank National Association: 362,459 shares worth $9.83M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q1 2023, an estimated $323M increase.
- Rafferty Asset Management's biggest Q1 2023 reduction was iShares Core S&P 500 ETF, cutting an estimated $45M.
- Rafferty Asset Management fully exited SVB Financial Group in Q1 2023, selling an estimated $7.88M.
- Rafferty Asset Management's ten largest holdings make up 32% of its $14.8B portfolio in Q1 2023.
- Rafferty Asset Management opened 65 new positions and closed 45 in Q1 2023.
- Rafferty Asset Management's portfolio value rose 24% quarter-over-quarter to $14.8B.
Based on Rafferty Asset Management's 13F filing for Q1 2023, filed 11 May 2023.